BioSpace - Synageva BioPharma News, Search Jobs, Events

BioSpace Collaborative

Academic/Biomedical Research
News & Jobs

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

<script language="javascript" src="http://at.ontargetjobs.com/addyn/3.0/701/2449103/0/681/ADTECH;loc=700;target=_blank;key=key1+key2+key3+key4;grp=[group]"></script><noscript><a href="http://at.ontargetjobs.com/adlink/3.0/701/2449103/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" target="_blank"><img src="http://at.ontargetjobs.com/adserv/3.0/701/2449103/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" border="0" width="160" height="240"></a></noscript>

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile

Synageva BioPharma

Corporate Offices
128 Spring Street, Suite 520
Lexington Massachusetts 02421 U.S.A.
Phone: 781-890-1111 Fax: 781-890-1114

Synageva BioPharma is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need. Our lead program, SBC-102, an enzyme replacement therapy for LAL Deficiency, is currently being evaluated in global Phase I/II clinical trials. SBC-102 has been granted orphan designations by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency and fast track designation by the FDA. Synageva has several protein therapeutics focused on life threatening conditions in its pipeline. The Company has assembled a team with a proven record of bringing orphan therapies to patients.

Key Statistics

Email: info@synageva.com
Ownership: Public

Web Site: Synageva BioPharma
Employees:
Symbol: GEVA

Industry
Biopharmaceutical

Company News

Synageva BioPharma (GEVA) to Present at the Jefferies and Co. 2013 Global Healthcare Conference 5/23/2013 7:26:22 AM More...

Synageva BioPharma (GEVA)'s Sebelipase Alfa Receives Breakthrough Therapy Designation for Early Onset LAL Deficiency From the FDA 5/20/2013 10:43:59 AM More...

Synageva BioPharma (GEVA) Joins the International MPS Network in Support of MPS Awareness Day 2013 5/15/2013 10:00:18 AM More...

Synageva BioPharma (GEVA) Reports First Quarter 2013 Financial Results 5/8/2013 7:50:28 AM More...

Synageva BioPharma (GEVA) Execs Got 28 Pct Compensation Hike in 2012 4/26/2013 7:42:44 AM More...

Synageva BioPharma (GEVA) Release: Late Onset LAL Deficiency (CESD) Literature Review Published in the Journal of Hepatology 3/26/2013 11:22:24 AM More...

Synageva BioPharma (GEVA) Reports 2012 Full Year Financial Results 3/12/2013 6:17:20 AM More...

Synageva BioPharma (GEVA) to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 11 3/4/2013 6:16:43 AM More...

Synageva BioPharma (GEVA) to Present at the Cowen and Company 33rd Annual Health Care Conference 2/26/2013 9:27:56 AM More...

Synageva BioPharma (GEVA) Initiates Dosing in Phase 3 Trial of Sebelipase Alfa in Children and Adults Wth Late Onset LAL Deficiency 2/11/2013 9:44:24 AM More...

1